Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial-Reference-Cited by-同舟云学术

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Published:2021-01 Issue:1 Volume:9 Page:22-31
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Wheeler David C,Stefánsson Bergur V,Jongs Niels,Chertow Glenn M,Greene Tom,Hou Fan Fan,McMurray John J V,Correa-Rotter Ricardo,Rossing Peter,Toto Robert D,Sjöström C David,Langkilde Anna Maria,Heerspink Hiddo J L

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference26 articles.

1. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes;Wheeler;Diabetes Ther,2020

2. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

3. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

4. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus;Cherney;Circulation,2014

5. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial;Cherney;Lancet Diabetes Endocrinol,2020

Cited by 341 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study;Diabetes, Obesity and Metabolism;2024-09-02

2. Global forecasting of chronic kidney disease mortality rates and numbers with the generalized additive model;BMC Nephrology;2024-09-02

3. Mendelian randomization study of sodium–glucose cotransporter 2 inhibitors in cardiac and renal diseases;Journal of International Medical Research;2024-08

4. The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy;Cell Reports Medicine;2024-08

5. Peripheral artery disease, chronic kidney disease, and recurrent admissions for acute decompensated heart failure: The ARIC study;Atherosclerosis;2024-08